# Louisiana Man Achieves Functional Cure for Sickle Cell Disease
Daniel Cressy of Louisiana has become the first person in his region to achieve functional remission of sickle cell disease, marking a milestone in gene therapy treatment for the inherited blood disorder. Cressy received a cutting-edge therapy that modifies his own stem cells to produce healthy hemoglobin, eliminating the painful crises and organ damage that typically define sickle cell disease.
Sickle cell disease affects roughly 100,000 Americans, with the highest prevalence among Black populations. The condition causes red blood cells to become rigid and crescent-shaped, leading to severe pain, organ failure, strokes, and shortened lifespans. Cressy's breakthrough involved extracting his bone marrow stem cells, genetically modifying them in the laboratory to correct the hemoglobin defect, and then reinfusing them back into his body.
This approach differs from traditional bone marrow transplants because it uses the patient's own cells rather than donor cells, eliminating rejection risks and the need for immunosuppression medications. Gene therapy has shown remarkable results in clinical trials over the past few years. The FDA approved two gene therapies for sickle cell disease: Casgevy, developed by CRISPR Therapeutics and Vertex Pharmaceuticals, and Lyfgenia from Bluebird Bio. Both have demonstrated sustained remission in most treated patients.
Cressy's recovery represents hope for families managing sickle cell disease. He no longer experiences vaso-occlusive crises, the unpredictable pain episodes that disrupt daily life. His hemoglobin levels now fall within normal ranges, and imaging shows no organ damage progression.
The treatment remains expensive and available only at specialized medical centers, creating access barriers for many patients. Insurance